Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Bill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Valeant Pharma (VRX) Moves Off Lows on Bill Miller Comments
- PL Capital Advisors Raises Stake in Banc of California (BANC) to 6.7%; Seeks to Speak with Management
- Time Warner (TWX) volatility elevated into AT&T (T) deal
Create E-mail Alert Related CategoriesHedge Funds, Trader Talk
Related EntitiesWilliam Ackman, Pershing Square Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!